In early April, a guideline was released to provide dosing recommendations for 6-mercaptopurine (6-MP) in adult acute lymphoblastic leukaemia (ALL) patients based on their TPMT and NUDT15 genotypes.
The North Thames Genomic Medicine Service is hosting an education and training webinar based on the content of this guideline that will aim to explain:
• The role of 6-MP in the treatment of ALL and it’s mechanism of action
• The role of TPMT and NUDT15 in the metabolism and detoxification of 6-mercaptopurine
• Common variant alleles that contribute to reduced or absent TPMT/NUDT15 enzyme activity and how this is linked to increased myelosuppression in your patients
• The importance of genetic testing for this patient cohort and how to implement dose modifications based upon a patient’s phenotype
This webinar is open to all healthcare professionals; it will be an interactive session with an opportunity to ask any questions you might have.
You only need to attend the workshop once. Dates available:
Monday 15 May, 4pm - 5:30pm
Wednesday 14 June, 4pm - 5:30pm
